Safety and Efficacy of Eluxadoline in Patients with Irritable Bowel Syndrome-Diarrhea With or Without Bile Acid Diarrhea: Open-Label Study

Vijayvargiya, Priya; Breen‐Lyles, Margaret K.; Nord, Sara Linker; Maselli, Daniel B.; Busciglio, Irene; Boinpally, Ramesh; Muslin, Anna; Carrothers, Timothy J.; Camilleri, Michael

doi:10.1007/s10620-022-07379-x

Cited by 4 publications

(3 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of eluxadoline in patients with BAD was studied in a single-center, open-label study of 24 patients with IBS-D, 12 of whom had BAD. In this study, it was shown that eluxadoline improved stool consistency and decreased abdominal pain in patients with IBS-D regardless of BAD status [41].…”

Section: Eluxadolinementioning

confidence: 61%

Bile acid diarrhea – as bad as it gets?

BouSaba

Camilleri

2023

Current Opinion in Gastroenterology

Self Cite

View full text Add to dashboard Cite

Purpose of review Bile acid diarrhea (BAD) is a common but under-recognized gastrointestinal condition that manifests with increased stool frequency and urgency, and a looser stool consistency. The aim of this review is to present recent advances in the pathophysiology, mechanisms, manifestations, diagnosis, and treatment of BAD. Recent findings Patients with BAD have evidence of accelerated colonic transit, increased gut mucosal permeability, altered stool microbiome composition, and decreased quality of life. Single, random stool measurements of bile acids, alone or in combination with fasting serum 7-alpha-hydroxy-4-cholesten-3-one, have shown good sensitivity and specificity for the diagnosis of BAD. Novel therapeutic approaches include farnesoid X receptor agonists and glucagon-like peptide 1 agonists. Summary Recent research has led to a better understanding of the pathophysiology and mechanisms of BAD, which might pave the way towards more targeted treatment strategies for BAD. Newer, more affordable, and easier diagnostic methods facilitate the diagnosis of BAD.

show abstract

Section: Eluxadolinementioning

confidence: 61%

Bile acid diarrhea – as bad as it gets?

BouSaba

Camilleri

2023

Current Opinion in Gastroenterology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Indeed, a posthoc analysis of the above-mentioned trials and a subsequent study confirmed its safety and efficacy up to 52 weeks of treatment in patients with IBS-D not responding to loperamide, 89,90 while a recent study reported its efficacy also on patients with IBS-D with concurrent bile acid diarrhea. 91 Finally, an updated metaanalysis of 42 trials performed a head-to-head comparison of eluxadoline with antispasmodics and concluded that eluxadoline was at least as effective as antispasmodics, but due to the higher amount of adverse events reported, antispasmodics still represent the first choice for the treatment of IBS-D. 92…”

Section: Eluxadolinementioning

confidence: 99%

Management of Irritable Bowel Syndrome With Diarrhea

Marasco,

Cremon,

Barbaro

et al. 2024

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

Irritable bowel syndrome (IBS) with diarrhea (IBS-D) affects ~1% of the general population and is characterized by abdominal pain associated with diarrhea. IBS-D symptoms significantly impact the quality of life of patients. Major uncertainties remain regarding the optimal management of these patients. Several therapies have been investigated over the years for the treatment of IBS-D. In the initial management, commonly prescribed approaches with an effect on global IBS symptoms include a low Fermentable Oligo-, Di-, Mono-Saccharides and Polyols diet and probiotics, while antispasmodics are used for targeting abdominal pain and loperamide for diarrhea only. Additional therapeutic options for the relief of global IBS symptoms include rifaximin, 5-HT3 antagonists, gut-directed psychological therapies, and eluxadoline, while tricyclic antidepressants can target abdominal pain and bile acid sequestrants diarrhea. Promising evidence exists for the use of mesalazine and fecal microbiota transplantation in IBS-D, although further evidence is needed for definitive conclusions regarding their efficacy.

show abstract

“…In this issue of Digestive Diseases and Sciences, Vijayvargiya et al [7] from the Mayo Clinic performed a rigorous, open-label cohort study on patients meeting Rome IV criteria for IBS-D who received eluxadoline at its FDAapproved dose of 100 mg twice daily for 4 weeks (including an appropriate 2-week run-in period). The purpose of the study was to distinguish pathophysiologic entities such as BAD from all-encompassing symptom-based classifications such as IBS-D. All patients underwent baseline diagnostics for bile acid diarrhea using fasting serum 7α-hydroxy-4cholesten-3-one (7α-C4) levels, a biomarker of hepatic bile acid synthesis; this test has been previously validated to have a sensitivity of 90% and specificity of 79% to detect bile acid malabsorption [8].…”

mentioning

confidence: 99%

Delta Variant: Expanding the Indication for Eluxadoline to Bile Acid Diarrhea

Shah

2022

Dig Dis Sci

View full text Add to dashboard Cite

Safety and Efficacy of Eluxadoline in Patients with Irritable Bowel Syndrome-Diarrhea With or Without Bile Acid Diarrhea: Open-Label Study

Cited by 4 publications

References 35 publications

Bile acid diarrhea – as bad as it gets?

Bile acid diarrhea – as bad as it gets?

Management of Irritable Bowel Syndrome With Diarrhea

Delta Variant: Expanding the Indication for Eluxadoline to Bile Acid Diarrhea

Contact Info

Product

Resources

About